Speaking at the third Breast Cancer Campaign Scientific Conference in London, Professor Rob Coleman, from the University of Sheffield´s Academic Unit of Clinical Oncology, highlighted the top developments in treating metastatic breast cancer-cancer that has spread to other parts of the body.
Prevention of metastases, through improved treatments alongside surgery, have rapidly improved the prognosis in breast cancer. Additionally, in those patients who do develop metastatic breast cancer, new treatments are steadily converting the disease into a more chronic illness where good quality life can be enjoyed for several years.
Professor Rob Coleman said: “There is much to be excited about. The introduction of targeted treatments such as herceptin, lapatinib and organ specific treatments such as bisphosphonates and denosumab are providing clinicians with increased options for prolonging the lives of women with metastatic breast cancer.
“Preliminary research funded by Breast Cancer Campaign has played a major role in informing clinical trials. In Sheffield we are now testing the drug combination of chemotherapy and zoledronic acid to prevent metastasis in patients. Pre-clinical results are very exciting, and if confirmed in the ongoing clinical trials could change the way breast cancer patients are treated.”
Notes for Editors: Breast Cancer Campaign aims to beat breast cancer by funding innovative world-class research to understand how breast cancer develops, leading to improved diagnosis, treatment, prevention and cure. Currently it supports 113 research projects, worth over £17million, in 40 centres of excellence across the UK and Ireland. Breast cancer is the most common cancer in the UK and accounts for nearly one in three of all cancers in women. In the UK, nearly 46,000 new cases of breast cancer are diagnosed each year – that´s 125 a day.
For further information please contact: Lauren Anderson, Media Relations Officer, on 0114 2221046 or email email@example.com